Sun Pharma to Acquire Organon for $11.75 Billion in Cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy OGN?
Source: seekingalpha
- Significant Deal Size: Sun Pharmaceutical has agreed to acquire Organon for an enterprise value of $11.75 billion, marking one of the largest healthcare transactions of 2023, which is expected to significantly enhance the company's market position.
- Shareholder Returns: Under the agreement, Organon shareholders will receive $14 per share in cash, reflecting recognition of Organon's future potential while providing Sun Pharma with an opportunity to expand its product portfolio.
- Financial Impact: Post-acquisition, Sun Pharma's net debt to EBITDA ratio is expected to reach 2.3 times, indicating a cautious approach to financing structure to support future growth.
- Market Expansion: This acquisition will enhance Sun Pharma's capabilities in women's health and biosimilars while expanding its footprint in developed markets like the U.S. and Europe, with projected combined annual revenues of $12.4 billion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 8.600
Low
5.00
Averages
8.50
High
12.00
Current: 8.600
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sun Pharma to Acquire Organon for $11.75 Billion in Cash
- Significant Deal Size: Sun Pharmaceutical has agreed to acquire Organon for an enterprise value of $11.75 billion, marking one of the largest healthcare transactions of 2023, which is expected to significantly enhance the company's market position.
- Shareholder Returns: Under the agreement, Organon shareholders will receive $14 per share in cash, reflecting recognition of Organon's future potential while providing Sun Pharma with an opportunity to expand its product portfolio.
- Financial Impact: Post-acquisition, Sun Pharma's net debt to EBITDA ratio is expected to reach 2.3 times, indicating a cautious approach to financing structure to support future growth.
- Market Expansion: This acquisition will enhance Sun Pharma's capabilities in women's health and biosimilars while expanding its footprint in developed markets like the U.S. and Europe, with projected combined annual revenues of $12.4 billion.
See More
Sun Pharma to Acquire Organon for $14.00 per Share in Cash
- Transaction Overview: Sun Pharma has entered into a definitive agreement to acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitiveness in the global pharmaceutical market.
- Financial Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with combined revenues of $12.4 billion, while EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Market Strategy: This acquisition will enable Sun Pharma to enter the biosimilars market, positioning it as a top-10 global player, while also strengthening its market position in women's health and creating a platform for future growth.
- Shareholder Value: The Organon Board believes this all-cash transaction offers compelling immediate value to shareholders, with the deal expected to close in early 2027, subject to regulatory approvals and shareholder voting.
See More
Sun Pharmaceutical to Acquire Organon for $11.75 Billion
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
See More
Sun Pharma to Acquire Organon for $14.00 per Share
- Transaction Details: Sun Pharma will acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitive position in the global pharmaceutical market.
- Market Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with a combined revenue of $12.4 billion, further solidifying its leadership in women's health and biosimilars.
- Financial Outlook: Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, and post-acquisition, Sun Pharma's EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Strategic Synergies: This acquisition will not only integrate Organon's product portfolio and global reach but also provide Sun Pharma with an entry into the biosimilars market, expected to unlock significant revenue growth potential.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
Organon & Co Options Volume Surges Significantly
- Surge in Options Volume: Organon & Co's options trading volume reached 70,867 contracts today, representing approximately 7.1 million shares, which constitutes 93.4% of its average daily trading volume of 7.6 million shares over the past month, indicating strong market interest in its future performance.
- High Liquidity Options: Notably, the $11 strike call option expiring on May 15, 2026, saw a trading volume of 10,996 contracts today, equating to about 1.1 million shares, suggesting bullish sentiment among investors at this price level.
- CS Disco Inc Options Activity: In parallel, CS Disco Inc recorded an options trading volume of 1,695 contracts, representing approximately 169,500 shares, which is about 89% of its average daily trading volume of 190,370 shares over the past month, indicating market interest in this company as well.
- Market Trend Analysis: The high trading volumes of these options contracts reflect investor optimism regarding the future trajectories of Organon and CS Disco Inc, which could influence their stock price volatility and overall market sentiment.
See More
Sun Pharma to Acquire Organon for $11.75 Billion in Cash
- Significant Deal Size: Sun Pharmaceutical has agreed to acquire Organon for an enterprise value of $11.75 billion, marking one of the largest healthcare transactions of 2023, which is expected to significantly enhance the company's market position.
- Shareholder Returns: Under the agreement, Organon shareholders will receive $14 per share in cash, reflecting recognition of Organon's future potential while providing Sun Pharma with an opportunity to expand its product portfolio.
- Financial Impact: Post-acquisition, Sun Pharma's net debt to EBITDA ratio is expected to reach 2.3 times, indicating a cautious approach to financing structure to support future growth.
- Market Expansion: This acquisition will enhance Sun Pharma's capabilities in women's health and biosimilars while expanding its footprint in developed markets like the U.S. and Europe, with projected combined annual revenues of $12.4 billion.
See More
Sun Pharma to Acquire Organon for $14.00 per Share in Cash
- Transaction Overview: Sun Pharma has entered into a definitive agreement to acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitiveness in the global pharmaceutical market.
- Financial Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with combined revenues of $12.4 billion, while EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Market Strategy: This acquisition will enable Sun Pharma to enter the biosimilars market, positioning it as a top-10 global player, while also strengthening its market position in women's health and creating a platform for future growth.
- Shareholder Value: The Organon Board believes this all-cash transaction offers compelling immediate value to shareholders, with the deal expected to close in early 2027, subject to regulatory approvals and shareholder voting.
See More
Sun Pharmaceutical to Acquire Organon for $11.75 Billion
- Acquisition Scale: Sun Pharmaceutical Industries is set to acquire Organon in an all-cash deal valued at approximately $11.75 billion, including debt, indicating the company's intent to expand its footprint in the global pharmaceutical market.
- Per Share Purchase Price: Under the agreement, Sun Pharma will buy all outstanding shares of Organon for $14.00 per share in cash, a price that reflects confidence in Organon's future growth potential.
- Market Positioning: This acquisition will grant Sun Pharma full ownership of Organon, which focuses on women's health, biosimilars, and established medicines, thereby enhancing its competitive edge in these critical sectors.
- Strategic Implications: Through this acquisition, Sun Pharma not only expands its product portfolio but also solidifies its position in the global pharmaceutical industry, particularly increasing its influence in the women's health segment.
See More
Sun Pharma to Acquire Organon for $14.00 per Share
- Transaction Details: Sun Pharma will acquire Organon for $14.00 per share in cash, valuing the deal at $11.75 billion, which will enhance Sun Pharma's competitive position in the global pharmaceutical market.
- Market Impact: Post-merger, Sun Pharma is expected to rank among the top 25 global pharmaceutical companies with a combined revenue of $12.4 billion, further solidifying its leadership in women's health and biosimilars.
- Financial Outlook: Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, and post-acquisition, Sun Pharma's EBITDA and cash flow are projected to nearly double, supporting its debt reduction strategy.
- Strategic Synergies: This acquisition will not only integrate Organon's product portfolio and global reach but also provide Sun Pharma with an entry into the biosimilars market, expected to unlock significant revenue growth potential.
See More
US Stocks Close Higher: S&P 500 Hits All-Time High
- S&P 500 Hits Record High: The S&P 500 index rose by 0.80%, closing at an all-time high, reflecting market optimism about economic recovery, particularly driven by technology stocks, which further solidifies investor confidence.
- Intel's Strong Performance: Intel's stock surged over 23% after forecasting Q2 revenue between $13.8 billion and $14.8 billion, significantly exceeding the $13.04 billion expectation, indicating strong confidence in the semiconductor industry's potential driven by artificial intelligence, which may spark increased investment in the sector.
- Consumer Confidence Rebounds: The University of Michigan's consumer sentiment index was revised upward to 49.8, surpassing the expected 48.5, suggesting an increase in consumer confidence regarding economic prospects, which could drive consumer spending and economic growth.
- International Dynamics Affecting Markets: Progress in US-Iran negotiations has boosted market sentiment; despite tensions in the Strait of Hormuz, optimism about future talks may alleviate energy price pressures and promote stock market gains.
See More
Organon & Co Options Volume Surges Significantly
- Surge in Options Volume: Organon & Co's options trading volume reached 70,867 contracts today, representing approximately 7.1 million shares, which constitutes 93.4% of its average daily trading volume of 7.6 million shares over the past month, indicating strong market interest in its future performance.
- High Liquidity Options: Notably, the $11 strike call option expiring on May 15, 2026, saw a trading volume of 10,996 contracts today, equating to about 1.1 million shares, suggesting bullish sentiment among investors at this price level.
- CS Disco Inc Options Activity: In parallel, CS Disco Inc recorded an options trading volume of 1,695 contracts, representing approximately 169,500 shares, which is about 89% of its average daily trading volume of 190,370 shares over the past month, indicating market interest in this company as well.
- Market Trend Analysis: The high trading volumes of these options contracts reflect investor optimism regarding the future trajectories of Organon and CS Disco Inc, which could influence their stock price volatility and overall market sentiment.
See More
